Point72 Asset Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $146M | Buy |
1,826,537
+1,382,170
| +311% | +$114M | 0.19% | 101 |
|
|
2025
Q4 | $37.9M | Sell |
444,367
-287,691
| -39% | -$23.6M | 0.04% | 537 |
|
|
2025
Q3 | $56.9M | Sell |
732,058
-2,307,323
| -76% | -$180M | 0.1% | 237 |
|
|
2025
Q2 | $238M | Buy |
3,039,381
+1,570,648
| +107% | +$117M | 0.47% | 28 |
|
|
2025
Q1 | $106M | Buy |
1,468,733
+880,527
| +150% | +$63M | 0.24% | 95 |
|
|
2024
Q4 | $43.5M | Buy |
+588,206
| New | +$41.2M | 0.1% | 247 |
|
|
2024
Q3 | – | Sell |
-444,162
| Closed | -$41M | – | 2090 |
|
|
2024
Q2 | $41M | Sell |
444,162
-2,526,642
| -85% | -$224M | 0.11% | 250 |
|
|
2024
Q1 | $284M | Buy |
+2,970,804
| New | +$250M | 0.69% | 13 |
|
|
2023
Q4 | – | Sell |
-22,199
| Closed | -$1.54M | – | 2339 |
|
|
2023
Q3 | $1.54M | Buy |
+22,199
| New | +$1.78M | ﹤0.01% | 1207 |
|
|
2023
Q2 | – | Sell |
-385
| Closed | -$33.5K | – | 2353 |
|
|
2023
Q1 | $31.8K | Buy |
+385
| New | +$30.3K | ﹤0.01% | 1886 |
|
|
2021
Q2 | – | Sell |
-579,142
| Closed | -$48.4M | – | 1028 |
|
|
2021
Q1 | $48.4M | Buy |
+579,142
| New | +$49M | 0.23% | 115 |
|
|
2020
Q4 | – | Sell |
-119,415
| Closed | -$9.53M | – | 970 |
|
|
2020
Q3 | $9.53M | Sell |
119,415
-367,269
| -75% | -$28.7M | 0.05% | 426 |
|
|
2020
Q2 | $33.6M | Buy |
486,684
+244,137
| +101% | +$17.3M | 0.22% | 125 |
|
|
2020
Q1 | $15.3M | Buy |
242,547
+164,112
| +209% | +$11.8M | 0.12% | 241 |
|
|
2019
Q4 | $6.1M | Sell |
78,435
-75,888
| -49% | -$5.93M | 0.03% | 468 |
|
|
2019
Q3 | $11.3M | Buy |
154,323
+120,120
| +351% | +$8.44M | 0.07% | 331 |
|
|
2019
Q2 | $2.11M | Sell |
34,203
-130,857
| -79% | -$7.91M | 0.01% | 642 |
|
|
2019
Q1 | $10.5M | Sell |
165,060
-33,540
| -17% | -$1.91M | 0.05% | 386 |
|
|
2018
Q4 | $10.1M | Buy |
198,600
+184,800
| +1,339% | +$9.35M | 0.05% | 409 |
|
|
2018
Q3 | $801K | Buy |
+13,800
| New | +$675K | ﹤0.01% | 866 |
|
|
2018
Q2 | – | Sell |
-600,000
| Closed | -$27.9M | – | 1031 |
|
|
2018
Q1 | $27.9M | Buy |
600,000
+210,000
| +54% | +$9.12M | 0.12% | 223 |
|
|
2017
Q4 | $14.7M | Sell |
390,000
-1,033,485
| -73% | -$37.9M | 0.06% | 375 |
|
|
2017
Q3 | $51.9M | Buy |
1,423,485
+84,285
| +6% | +$3.21M | 0.23% | 108 |
|
|
2017
Q2 | $52.8M | Buy |
1,339,200
+999,975
| +295% | +$36.5M | 0.3% | 89 |
|
|
2017
Q1 | $10.6M | Sell |
339,225
-1,089,975
| -76% | -$34.1M | 0.06% | 390 |
|
|
2016
Q4 | $44.6M | Buy |
1,429,200
+415,500
| +41% | +$13.5M | 0.31% | 87 |
|
|
2016
Q3 | $40.7M | Buy |
1,013,700
+431,100
| +74% | +$16.2M | 0.29% | 90 |
|
|
2016
Q2 | $19.4M | Buy |
582,600
+541,500
| +1,318% | +$18.5M | 0.13% | 189 |
|
|
2016
Q1 | $1.21M | Sell |
41,100
-408,300
| -91% | -$11.3M | 0.01% | 605 |
|
|
2015
Q4 | $11.8M | Sell |
449,400
-949,800
| -68% | -$24.7M | 0.1% | 247 |
|
|
2015
Q3 | $33.2M | Buy |
1,399,200
+360,000
| +35% | +$8.69M | 0.26% | 114 |
|
|
2015
Q2 | $24.7M | Sell |
1,039,200
-397,200
| -28% | -$8.96M | 0.17% | 171 |
|
|
2015
Q1 | $34.1M | Buy |
+1,436,400
| New | +$32.2M | 0.23% | 128 |
|
|
2014
Q4 | – | Sell |
-1,237,800
| Closed | -$21.1M | – | 707 |
|
|
2014
Q3 | $21.1M | Buy |
+1,237,800
| New | +$19.5M | 0.16% | 175 |
|
Other funds holding EW
VCM
VPM
Point72 Asset Management's EW Position: Q1 2026 in Review
Point72 Asset Management increased its Edwards Lifesciences (EW) stake by 311% in Q1 2026, buying an estimated $114M and bringing the position to 1,826,537 shares worth $146M. The position accounts for 0.19% of the portfolio, ranked #101.
Point72 Asset Management first reported a position in EW in Q3 2014 and has held it in 34 quarters since. The position peaked at $284M in Q1 2024. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Point72 Asset Management held 1,826,537 shares of Edwards Lifesciences worth $146M as of Q1 2026.
- Point72 Asset Management bought 1,382,170 Edwards Lifesciences shares in Q1 2026, an estimated $114M.
- Edwards Lifesciences made up 0.19% of Point72 Asset Management's portfolio in Q1 2026, its #101 holding.
- Point72 Asset Management first reported a position in Edwards Lifesciences in Q3 2014 and has held it in 34 quarters since.
- Point72 Asset Management's Edwards Lifesciences position peaked at $284M in Q1 2024.
- 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.